Louisiana 2022 Regular Session

Louisiana Senate Bill SB348

Introduced
3/4/22  
Refer
3/4/22  
Refer
3/4/22  
Refer
3/14/22  
Refer
3/14/22  
Report Pass
5/9/22  
Report Pass
5/9/22  
Engrossed
5/16/22  
Engrossed
5/16/22  
Refer
5/17/22  
Refer
5/17/22  
Report Pass
5/23/22  
Report Pass
5/23/22  
Enrolled
6/6/22  
Enrolled
6/6/22  
Chaptered
6/18/22  

Caption

Provides for a process for a prior authorization for a particular healthcare service, procedure, or prescription drug. (7/1/22) (EN SEE FISC NOTE See Note)

Impact

The implementation of SB348 is expected to significantly impact state laws concerning healthcare regulations. The requirement for health plans to disclose their criteria for prior authorizations will likely lead to improved operational efficiency for healthcare providers as they navigate the authorization process. Additionally, it addresses a common pain point for healthcare providers and patients alike—the ambiguity often surrounding what is required for authorization of services. Such measures could lead to a reduction in delays and better healthcare outcomes for patients in Louisiana.

Summary

Senate Bill 348 aims to enhance transparency in the prior authorization process for healthcare services, procedures, and prescription drugs in Louisiana. By mandating that every health plan provide necessary medical criteria for prior authorization requests, the bill seeks to streamline the communication between healthcare providers and health plans. The legislation requires that within one business day of a request, relevant information about prior authorization requirements must be provided to healthcare providers to facilitate timely patient care. This ensures that healthcare professionals are equipped with the information they need to effectively manage patient treatment plans.

Sentiment

The sentiment surrounding SB348 appears to be largely positive amongst healthcare providers who view the bill as a step towards mitigating inefficiencies in the healthcare authorization process. Supporters argue that increased transparency promotes trust and facilitates better provider-patient dynamics. However, there may also be concerns regarding how health plans implement these requirements and whether they will comply fully and promptly, which could affect the overall effectiveness of the law.

Contention

While SB348 is seen as a progressive step towards healthcare reforms, it does bring forth potential contention regarding the readiness of health plans to adapt to these new requirements. Opponents may voice concerns about the feasibility of implementing such mandates within existing administrative frameworks and whether this could impose additional operational costs on health plans. Overall, the legislation embodies a significant shift in prioritizing transparency in healthcare interactions, yet its eventual success will depend on effective enforcement and cooperation from all stakeholders involved.

Companion Bills

No companion bills found.

Previously Filed As

LA SB164

Provides relative to prior authorization for services, procedures, and pharmaceuticals. (gov sig) (RE1 INCREASE SG EX See Note)

LA SB77

Provides relative to prior authorization of prescription drugs. (8/1/22) (EN NO IMPACT See Note)

LA SB29

Provides relative to a single uniform prescription drug prior authorization form. (See Act) (RE SEE FISC NOTE SG EX See Note)

LA SB67

Provides for the reorganization and modernization of the Administrative Procedure Act. (8/1/22) (EN NO IMPACT See Note)

LA HB468

Provides relative to utilization review standards and approval procedures for healthcare service claims submitted by healthcare providers (EN NO IMPACT See Note)

LA SB188

Provides for utilization review and approval procedures of claims for healthcare provider services. (gov sig)

LA HB839

Provides relative to a marketplace for consumers seeking healthcare services and procedures

LA SB260

Provides for the organization of the Office of Group Benefits. (1/1/16) (EN SEE FISC NOTE SG EX See Note)

LA H6317

Prohibits an insurer from imposing a requirement of prior authorization for any admission, item, service, treatment, test, exam, study, procedure, or any generic or brand name prescription drug ordered by a primary care provider.

LA SB421

Provides the billing and collections procedure for surgical implants. (8/1/22) (OR SEE FISC NOTE SG EX)

Similar Bills

No similar bills found.